Showing 1141-1150 of 9850 results for "".
DermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinKey Components of an Effective Strategic Plan
https://practicaldermatology.com/topics/practice-management/key-components-of-an-effective-strategic-plan/23933/A number of actionable steps can effectively and efficiently ensure that your practice stays on track.A Dermatologist’s Guide to Marketing Skin Cancer Screenings
https://practicaldermatology.com/topics/practice-management/a-dermatologists-guide-to-marketing-skin-cancer-screenings/23932/As the mercury soars, bring prevention and professional skin checks out of the shadows and into the light.At Your Service: Championing Employee Leadership
https://practicaldermatology.com/topics/practice-management/at-your-service-championing-employee-leadership/23793/How to develop engaged staff members who perform at the owner level.Top Tips for Increasing Social Media Engagement
https://practicaldermatology.com/topics/practice-management/top-tips-for-increasing-social-media-engagement/23709/It takes time to grow your base, but if you know your audience and strategize, you can see gains.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyDermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesDermWireTV: Staff Vaccinations, Dupilumab Data, Rosacea Resource, Sensitive Skin Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-staff-vaccinations-dupilumab-data-rosacea-resource-sensitive-skin-week/19907/Most physicians have had a chance to be vaccinated, but staff may be a different story. Some practices are struggling with policies for mandated staff vaccines. The National Rosacea Society has updated its most popular educational booklet, “Understanding Rosacea.” New data highlight the potential imNew SEO Trends Dermatologists Should Anticipate in 2021
https://practicaldermatology.com/topics/practice-management/new-seo-trends-dermatologists-should-anticipate-in-2021/19900/Dermatology online marketing will have a surge of possible business in 2021 as people start moving back to requesting and seeking medical care again, especially once COVID-19 vaccines become widespread. Getting ahead of the SEO search curve now will give your office the advantage before the demand mThe Secret Sauce of Business Success During COVID-19
https://practicaldermatology.com/topics/practice-management/the-secret-sauce-of-business-success-during-covid-19/23424/How to run an efficient and successful business for the long run.